Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioCryst Pharmaceuticals Inc BCRX

Healthcare Biotechnology
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of... see more

Recent & Breaking News (NDAQ:BCRX)

BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Complement Activity with BCX9930 in C3G Patients

GlobeNewswire August 26, 2022

U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Pandemic Influenza Preparedness

GlobeNewswire August 25, 2022

BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia

GlobeNewswire August 18, 2022

BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones

GlobeNewswire August 4, 2022

BioCryst Resumes Enrollment in BCX9930 Clinical Program

GlobeNewswire August 4, 2022

BioCryst to Report Second Quarter 2022 Financial Results on August 4

GlobeNewswire July 21, 2022

BioCryst to Present at Upcoming Investor Conference

GlobeNewswire July 15, 2022

BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat)

GlobeNewswire July 1, 2022

BioCryst Announces ORLADEYO® (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022

GlobeNewswire June 22, 2022

BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Latin America

GlobeNewswire June 9, 2022

FDA Grants Fast Track Designation for BioCryst's ALK-2 Inhibitor, BCX9250

GlobeNewswire June 8, 2022

BioCryst Announces Approval of ORLADEYO® (berotralstat) by Swissmedic

GlobeNewswire June 7, 2022

BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks

GlobeNewswire June 6, 2022

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire June 1, 2022

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire May 6, 2022

BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones

GlobeNewswire May 5, 2022

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 4, 2022

European Medicines Agency Grants PRIME Designation to BioCryst's ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans Progressiva

GlobeNewswire April 27, 2022

BioCryst to Report First Quarter 2022 Financial Results on May 5

GlobeNewswire April 21, 2022

BioCryst to Present at Upcoming Investor Conference

GlobeNewswire April 11, 2022